Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term Effect of Modified, Low-dose PCSK9 Inhibitor Combined With Statins on Serum Lipids in Chinese Population With ACS
NCT05298475Phase 4Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2022
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in acute coronary syndrome (ACS) and dyslipidemia (3 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Total Cholesterol at 6 months, Triglyceride at 6 months and 2 more. Status: unknown.
02
Conditions
acute coronary syndrome (ACS)dyslipidemia
Beyond the preview
Go deeper on NCT05298475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05298475.